ARIUS Announces Changes to Board of Directors

    TORONTO, Dec. 6 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that Mr. James Rae has been appointed to the Company's Board
of Directors.
    "As CEO of Viron Therapeutics, a former CEO of other Canadian
biotechnology companies including Cangene, and a current director on several
boards, Mr. Rae will be a valuable addition to the ARIUS Board of Directors,"
said Dr. David Young, President and Chief Executive Officer of ARIUS.
"Furthermore, his experience in strategic value creation and sector
transactions will provide ARIUS with knowledgeable counsel as we advance
towards our first human clinical trials, planned for 2008."
    Mr. Rae brings to the ARIUS Board more than 30 years of experience in
manufacturing, marketing, finance and research & development for
pharmaceutical and biotechnology firms. He is currently the President and CEO
of Viron Therapeutics, a clinical stage biopharmaceutical company developing a
new class of anti-inflammatory therapeutics to treat and prevent human
inflammatory disorders. He is also the President and founder of Remedis, a
consultancy specializing in the restructuring and financing of healthcare
businesses. Prior to establishing Remedis, Mr. Rae was President and CEO of
Cangene, a publicly-listed biotech company. Most recently, he served as the
CEO of Cytochroma Inc., a Markham-based biotechnology company, which he
transitioned over an 18-month period from a research entity to a company with
advanced clinical development programs and a diversified product base. Mr. Rae
is presently Chairman of Aegera Therapeutics, Montreal, Chairman of Queen's
Scientific Breakthrough Fund and holds directorships in a number of Canadian
biotech companies.
    The Company also announced today that Diane Kalina has resigned from the
Board of Directors but will remain available to provide counsel to ARIUS as a
Consultant to the Board. Ms. Kalina is President of BioCatalyst Yorkton Ltd.,
a licensing and strategic alliance consulting company, and has recently been
named President and CEO of the biotech start-up company, Pharmaceutical
Development Corporation. "We would like to thank Diane for her contributions
to the ARIUS Board," said Dr. Young. "Her guidance was of great assistance to
the development of our business."

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 500
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00013708E

For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,,; James Smith, Investor
Relations, (416) 815-0700 ext. 229,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890